Green tea EGCG, T-cell function, and T-cell-mediated autoimmune encephalomyelitis

Journal of Investigative Medicine

Volumn 64, Issue 8, 2016, Pages 1213-1219

  Wu, Dayong ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Autoimmunity; Cytokines; Inflammation; Th17 Cells

Indexed keywords

CYTOKINE RECEPTOR; EPIGALLOCATECHIN GALLATE; CATECHIN; CYTOKINE;

ALLERGIC ENCEPHALOMYELITIS; ANTIOXIDANT ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL EXPANSION; CELL PROLIFERATION; DIET SUPPLEMENTATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOMODULATION; MOUSE MODEL; NONHUMAN; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TEA; TH1 CELL; TH17 CELL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; CATECHIN; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TEA;

EID: 85002497906     PISSN: 10815589     EISSN: 17088267     Source Type: Journal    
DOI: 10.1136/jim-2016-000158     Document Type: Article

References (71)

1. Ramesh E, Elanchezhian R, Sakthivel M, et al. Epigallocatechin gallate improves serum lipid profile and erythrocyte and cardiac tissue antioxidant parameters in Wistar rats fed an atherogenic diet. Fundam Clin Pharmacol 2008;22:275-84.
2. Ahmed S, Marotte H, Kwan K, et al. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc Natl Acad Sci USA 2008;105:14692-7.
3. Aktas O, Prozorovski T, Smorodchenko A, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 2004;173:5794-800.
4. Haqqi TM, Anthony DD, Gupta S, et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci USA 1999;96:4524-9.
5. Kim HR, Rajaiah R, Wu QL, et al. Green tea protects rats against autoimmune arthritis by modulating disease-related immune events. J Nutr 2008;138:2111-16.
6. Wang J, Ren Z, Xu Y, et al. Epigallocatechin-3-gallate ameliorates experimental autoimmune encephalomyelitis by altering balance among CD4+ T-cell subsets. Am J Pathol 2012;180:221-34.
7. Abboud PA, Hake PW, Burroughs TJ, et al. Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharmacol 2008;579:411-17.
8. Ran ZH, Chen C, Xiao SD. Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid. Biomed Pharmacother 2008;62:189-96.
9. Levites Y, Amit T, Mandel S, et al. Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J 2003;17:952-4.
10. Adhami VM, Siddiqui IA, Sarfaraz S, et al. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 2009;15:1947-53.
11. Ju J, Hong J, Zhou JN, et al. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 2005;65:10623-31.
12. Kundu JK, Surh YJ. Epigallocatechin gallate inhibits phorbol ester-induced activation of NF-kappa B and CREB in mouse skin: role of p38 MAPK. Ann N Y Acad Sci 2007;1095:504-12.
13. Yang CS, Liao J, Yang GY, et al. Inhibition of lung tumorigenesis by tea. Exp Lung Res 2005;31:135-44.
14. Bose M, Lambert JD, Ju J, et al. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 2008;138:1677-83.
15. Klaus S, Pultz S, Thone-Reineke C, et al. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. Int J Obes (Lond) 2005;29:615-23.
16. Wolfram S, Raederstorff D, Wang Y, et al. TEAVIGO (epigallocatechin gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass. Ann Nutr Metab 2005;49:54-63.
17. Pae M, Wu D. Immunomodulating effects of epigallocatechin-3-gallate from green tea: mechanisms and applications. Food Funct 2013;4:1287-303.
18. Hu ZQ, Toda M, Okubo S, et al. Mitogenic activity of (-)epigallocatechin gallate on B-cells and investigation of its structure-function relationship. Int J Immunopharmacol 1992;14:1399-407.
19. Wilasrusmee C, Kittur S, Siddiqui J, et al. In vitro immunomodulatory effects of ten commonly used herbs on murine lymphocytes. J Altern Complement Med 2002;8:467-75.
20. Kim JY, Kina T, Iwanaga Y, et al. Tea polyphenol inhibits allostimulation in mixed lymphocyte culture. Cell Transplant 2007;16:75-83.
21. Wu D, Guo Z, Ren Z, et al. Green tea EGCG suppresses T cell proliferation through impairment of IL-2/IL-2 receptor signaling. Free Radic Biol Med 2009;47:636-43.
22. Pae M, Ren Z, Meydani M, et al. Epigallocatechin-3-gallate directly suppresses T cell proliferation through impaired IL-2 utilization and cell cycle progression. J Nutr 2010;140:1509-15.
23. Watson JL, Vicario M, Wang A, et al. Immune cell activation and subsequent epithelial dysfunction by Staphylococcus enterotoxin B is attenuated by the green tea polyphenol (-)-epigallocatechin gallate. Cell Immunol 2005;237:7-16.
24. Pae M, Ren Z, Meydani SN, et al. Green tea EGCG suppresses specific antigen driven T cell response and affects CD4+ T cell differentiation. FASEB J 2010;24(1-MeetingAbstracts), 326.8.
25. Lyu SY, Park WB. Production of cytokine and NO by RAW 264.7 macrophages and PBMC in vitro incubation with flavonoids. Arch Pharm Res 2005;28:573-81.
26. Wang J, Pae M, Meydani SN, et al. Epigallocatechin-3-gallate inhibits expression of receptors for T cell regulatory cytokines and their downstream signaling in mouse CD4+ T cells. J Nutr 2012;142:566-71.
27. Lord JD, McIntosh BC, Greenberg PD, et al. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol 2000;164:2533-41.
28. Mui AL, Wakao H, Kinoshita T, et al. Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J 1996;15:2425-33.
29. Budagian V, Bulanova E, Paus R, et al. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 2006;17:259-80.
30. Jiang Q, Li WQ, Aiello FB, et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 2005;16:513-33.
31. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006;24:657-79.
32. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008;29:848-62.
33. Shim JH, Choi HS, Pugliese A, et al. (-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. J Biol Chem 2008;283:28370-9.
34. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
35. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
36. Firpo EJ, Koff A, Solomon MJ, et al. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol 1994;14:4889-901.
37. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372:570-3.
38. Lu M, Dou QP, Kitson RP, et al. Differential effects of proteasome inhibitors on cell cycle and apoptotic pathways in human YT and Jurkat cells. J Cell Biochem 2006;97:122-34.
39. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001;276:13322-30.
40. Wang J, Niu X, Meydani SN, et al. Epigallocatechin-3-gallate (EGCG) inhibits murine CD4+ T cell division and cell cycle progression through modulating cell cycle related-proteins. FASEB J 2015;29(Meeting Abstracts):593.10.
41. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 2006;6:329-33.
42. Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4T cell lineage with regulatory T cell ties. Immunity 2006;24:677-88.
43. Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52.
44. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
45. Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3 (-) effector T cells. Nat Immunol 2008;9:1347-55.
46. Elyaman W, Bradshaw EM, Uyttenhove C, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA 2009;106:12885-90.
47. Nowak EC, Weaver CT, Turner H, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009;206:1653-60.
48. Veldhoen M, Uyttenhove C, van Snick J, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008;9:1341-6.
49. Wang J, Pae M, Meydani SN, et al. Green tea epigallocatechin-3-gallate modulates differentiation of naive CD4(+) T cells into specific lineage effector cells. J Mol Med 2013;91:485-95.
50. Wong CP, Nguyen LP, Noh SK, et al. Induction of regulatory T cells by green tea polyphenol EGCG. Immunol Lett 2011;139:7-13.
51. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31.
52. Ando DG, Clayton J, Kono D, et al. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 1989;124:132-43.
53. Kuchroo VK, Anderson AC, Waldner H, et al. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol 2002;20:101-23.
54. Merrill JE, Kono DH, Clayton J, et al. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc Natl Acad Sci USA 1992;89:574-8.
55. Baker D, O'Neill JK, Turk JL. Cytokines in the central nervous system of mice during chronic relapsing experimental allergic encephalomyelitis. Cell Immunol 1991;134:505-10.
56. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992;176:1355-64.
57. Dardalhon V, Korn T, Kuchroo VK, et al. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008;31:252-6.
58. Domingues HS, Mues M, Lassmann H, et al. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS ONE 2010;5:e15531.
59. Kroenke MA, Carlson TJ, Andjelkovic AV, et al. IL-12-and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008;205:1535-41.
60. O'Connor RA, Prendergast CT, Sabatos CA, et al. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2008;181:3750-4.
61. Jager A, Dardalhon V, Sobel RA, et al. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009;183:7169-77.
62. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010;10:849-59.
63. Grant CR, Liberal R, Mieli-Vergani G, et al. Regulatory T-cells in autoimmune diseases: challenges, controversies and-yet-unanswered questions. Autoimmun Rev 2015;14:105-16.
64. Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression-a diverse arsenal for a moving target. Immunology 2008;124:13-22.
65. Zhang X, Koldzic DN, Izikson L, et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol 2004;16:249-56.
66. Kohm AP, Carpentier PA, Anger HA, et al. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 2002;169:4712-16.
67. Rieckmann P, Nunke K, Burchhardt M, et al. Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier. J Neuroimmunol 1993;47:133-40.
68. Sharief MK, Noori MA, Ciardi M, et al. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol 1993;43:15-21.
69. Bullard DC, Hu X, Schoeb TR, et al. Intercellular adhesion molecule-1 expression is required on multiple cell types for the development of experimental autoimmune encephalomyelitis. J Immunol 2007;178:851-7.
70. Kebir H, Ifergan I, Alvarez JI, et al. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 2009;66:390-402.
71. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009;10:514-23.